Literature DB >> 12913831

Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines.

Margaret B Rennels1.   

Abstract

Extensive local reactions are recognized to occur after administration of the fourth and fifth booster doses of diphtheria-tetanus-acellular pertussis (DTaP) vaccines. The incidence of these reactions is being delineated by prospective studies. Retrospective evaluations suggest that entire proximal limb swelling occurs in 2 to 6 percent of children given booster doses of DTaP vaccines. The reactions subside without sequelae, but they may be misdiagnosed as cellulitis and lead to unnecessary medical intervention. The pathogenesis of these reactions probably is multifactorial. Evidence suggests that both antigen content and prevaccination immunity have roles. Important, unanswered questions are the safety of revaccinating a child who previously has had an extensive local reaction and the safety of introducing further DTaP boosters into the adolescent and adult populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913831     DOI: 10.1016/s1045-1870(03)00033-5

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  14 in total

Review 1.  Pertussis vaccination for health care workers.

Authors:  Thomas J Sandora; Courtney A Gidengil; Grace M Lee
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

2.  Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children.

Authors:  Julie Rowe; Stephanie T Yerkovich; Peter Richmond; Devinda Suriyaarachchi; Elizabeth Fisher; Leonie Feddema; Richard Loh; Peter D Sly; Patrick G Holt
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Vaccination site reaction or bacterial cellulitis?

Authors:  Keswadee Lapphra; David Scheifele
Journal:  Paediatr Child Health       Date:  2009-04       Impact factor: 2.253

4.  Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Authors:  Roland Sänger; Ulrich Behre; Karl-Heinz Krause; Hans-Peter Loch; Peter Soemantri; Dietmar Herrmann; Eugenie Schmitz-Hauss; Joanne Wolter; Bernard Hoet
Journal:  Eur J Pediatr       Date:  2007-01-18       Impact factor: 3.183

5.  Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.

Authors:  Giuseppe Ferrera; Mario Cuccia; Gabriele Mereu; Giancarlo Icardi; Gianni Bona; Susanna Esposito; Federico Marchetti; Marc Messier; Sherine Kuriyakose; Karin Hardt
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

6.  Combination vaccines.

Authors:  David Ag Skibinski; Barbara C Baudner; Manmohan Singh; Derek T O'Hagan
Journal:  J Glob Infect Dis       Date:  2011-01

7.  Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children.

Authors:  Jeanet M Kemmeren; Nicoline A T van der Maas; Hester E de Melker
Journal:  Eur J Pediatr       Date:  2010-09-21       Impact factor: 3.860

8.  Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.

Authors:  Nathalie Mielcarek; Anne-Sophie Debrie; Dominique Raze; Julie Bertout; Carine Rouanet; Amena Ben Younes; Colette Creusy; Jacquelyn Engle; William E Goldman; Camille Locht
Journal:  PLoS Pathog       Date:  2006-07       Impact factor: 6.823

9.  Booster vaccination: the role of reduced antigen content vaccines as a preschool booster.

Authors:  Giovanni Gabutti; Cecilia Trucchi; Michele Conversano; Giambattista Zivelonghi; Giorgio Zoppi
Journal:  Biomed Res Int       Date:  2014-02-11       Impact factor: 3.411

Review 10.  Vaccination in elite athletes.

Authors:  Barbara C Gärtner; Tim Meyer
Journal:  Sports Med       Date:  2014-10       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.